Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Sirius Therapeutics Files Hong Kong IPO Application with siRNA Pipeline Targeting Coagulation and Cardiometabolic Diseases

Fineline Cube Apr 1, 2026
Company Deals

Gilead and Galapagos Forge $2.175 Billion T-Cell Engager Collaboration for Autoimmune Diseases Following Ouro Medicines Acquisition

Fineline Cube Apr 1, 2026
Company Deals

Merck & Co. Partners with Infinimmune for $838 Million Antibody Discovery Collaboration Using Human-First Platform

Fineline Cube Apr 1, 2026
Company Deals

Otsuka Pharmaceutical to Acquire Transcend Therapeutics for Up to $1.225 Billion to Expand Neuropsychiatric Pipeline

Fineline Cube Apr 1, 2026
Company Deals Digital

Abbott Integrates Precision Oncology Portfolio into Flatiron’s OncoEMR Platform to Streamline Cancer Care

Fineline Cube Mar 31, 2026
Policy / Regulatory

NMPA Finalizes Conditional Drug Approval Framework to Accelerate Access to Critical Medicines

Fineline Cube Mar 31, 2026
Company Drug

Fosun Pharma Secures NMPA Clearance for Two Novel Therapeutics: PD-1/IL-2 Fusion FXB0871 and Recombinant Hyaluronidase HLXTE-HAase02

Fineline Cube Apr 1, 2026
Company Drug

Rui Therapeutics Secures NMPA Approval for KN5501 CAR-NK Therapy in Autoimmune Diseases

Fineline Cube Apr 1, 2026
Company Deals

Alioth Biotech Raises RMB 100M in Series A Financing for Pharma Processing Products

Fineline Cube Oct 14, 2022

China-based Alioth Biotech (Shanghai) Co., Ltd has raised close to RMB 100 million (USD 13.9...

Company Deals

HICOMP MicroTech Raises RMB 100M in Series B+ Financing for Microfluidics Expansion

Fineline Cube Oct 14, 2022

China-based micro/nano technology developer HICOMP MicroTech (Suzhou) Co., Ltd has raised RMB 100 million (USD...

Company Drug

Kintor’s Dual c-Myc/GSPT1 Degradation Therapy GT19715 Shows Promise in Pre-Clinical Studies

Fineline Cube Oct 14, 2022

China-based Kintor Pharmaceutical Ltd (HKG: 9939) has published positive results from a pre-clinical study of...

Company Drug

CARsgen’s BCMA-Targeted CAR-T Therapy CT053 Gains Priority Review in China

Fineline Cube Oct 14, 2022

The Center for Drug Evaluation (CDE) website indicates that China-based chimeric antigen receptor (CAR)-T cell...

Company Drug

LianBio Cancels Phase III Trial for Truseltiq in China Amid Global Halt

Fineline Cube Oct 14, 2022

China-based LianBio (OTCMKTS: LIANY) revealed in an SEC filing that it is canceling work on...

Company Drug

Accutar Biotechnology Initiates Phase I Trial for ERα Targeting Degradation Molecule AC0682

Fineline Cube Oct 14, 2022

New Jersey-based Accutar Biotechnology Inc., which is heavily backed by Chinese funds, has announced the...

Policy / Regulatory R&D

CDE Releases Draft Guidelines for Extrapolating Adult Drug Data to Pediatric Use

Fineline Cube Oct 14, 2022

The Center for Drug Evaluation (CDE) has released the “Guidelines on Quantitative Methodology for Extrapolating...

Company Drug

RemeGen’s Telitacicept Receives FDA Orphan Drug Designation for Myasthenia Gravis

Fineline Cube Oct 13, 2022

China-based pharma firm RemeGen (HKG: 9995, SHA: 688331) has announced receiving Orphan Drug Designation (ODD)...

Company Deals

Jacobio Partners with Merck KGaA for KRAS G12C Inhibitor Clinical Study

Fineline Cube Oct 13, 2022

China-based Jacobio Pharmaceuticals Group Co., Ltd (HKG: 1167) has announced a clinical study collaboration partnership...

Company Medical Device

Hotgen Biotech Gains Regulatory Approvals in Saudi Arabia and India

Fineline Cube Oct 13, 2022

China-based Hotgen Biotech Co., Ltd (SHA: 688068) has announced receiving one certificate from the Saudi...

Company Drug

BeiGene’s Brukinsa Outperforms Imbruvica in Phase III ALPINE Study

Fineline Cube Oct 13, 2022

China-based biotech BeiGene Inc. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has announced that its Bruton’s...

Company

Hengrui Medicine’s Deputy GM Tao Weikang Resigns, Joins Qilu Pharma

Fineline Cube Oct 13, 2022

China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has announced that its deputy general manager...

Company Deals

Proxinse Medtech Raises Series A Funding for Endoscope Camera System

Fineline Cube Oct 13, 2022

Shenzhen Proxinse Medical Technology Co., Ltd, a provider of minimally invasive surgery endoscope camera systems...

Company Deals

AlphaLife Sciences Raises Series A+ Funding for Clinical Research SaaS

Fineline Cube Oct 13, 2022

China-based clinical research SaaS service provider AlphaLife Sciences has reportedly raised “tens of millions” of...

Company Drug

Aosaikang’s Neratinib Maleate API Market Filing Accepted by NMPA

Fineline Cube Oct 13, 2022

Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has announced that the market filing for its...

Drug Policy / Regulatory

Azvudine Included in China’s COVID-19 Treatment Protocol

Fineline Cube Oct 12, 2022

The National Healthcare Commission and the National Administration of Traditional Chinese Medicine have released a...

Company Drug

NMPA Approves IND Filing for Henan Genuine Biotech’s Long-Acting HIV Drug CL-197

Fineline Cube Oct 12, 2022

China-based Henan Genuine Biotech Co., Ltd’s investigational new drug (IND) filing for its oral long-acting...

Company Deals

WuXi Biologics Partners with Toregem BioPharma on Anti-USAG-1 Monoclonal Antibody

Fineline Cube Oct 12, 2022

China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has entered into...

Company Deals

BeiGene Partners with Amoy Diagnostics for Companion Diagnostics Development

Fineline Cube Oct 12, 2022

China-based biotech BeiGene Inc. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has entered into a partnership...

Company Medical Device

NMPA Approves Beijing Union Strong’s Intracranial Aneurysm Surgical Planning Software

Fineline Cube Oct 12, 2022

The National Medical Products Administration (NMPA) has approved the marketing of Beijing Union Strong Technology...

Posts pagination

1 … 594 595 596 … 645

Recent updates

  • Fosun Pharma Secures NMPA Clearance for Two Novel Therapeutics: PD-1/IL-2 Fusion FXB0871 and Recombinant Hyaluronidase HLXTE-HAase02
  • Rui Therapeutics Secures NMPA Approval for KN5501 CAR-NK Therapy in Autoimmune Diseases
  • Changchun High & New Receives NMPA Approval for GenSci161 Clinical Study in Endometriosis and Hidradenitis Suppurativa
  • Sirius Therapeutics Files Hong Kong IPO Application with siRNA Pipeline Targeting Coagulation and Cardiometabolic Diseases
  • Alphamab Oncology’s Anbenitamab Meets Primary Endpoint in Phase III HER2+ Breast Cancer Neoadjuvant Study
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Fosun Pharma Secures NMPA Clearance for Two Novel Therapeutics: PD-1/IL-2 Fusion FXB0871 and Recombinant Hyaluronidase HLXTE-HAase02

Company Drug

Rui Therapeutics Secures NMPA Approval for KN5501 CAR-NK Therapy in Autoimmune Diseases

Company Drug

Changchun High & New Receives NMPA Approval for GenSci161 Clinical Study in Endometriosis and Hidradenitis Suppurativa

Company Deals

Sirius Therapeutics Files Hong Kong IPO Application with siRNA Pipeline Targeting Coagulation and Cardiometabolic Diseases

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.